Key Details
Annual ROE
-19.07%Beta
-Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
May 16, 2023Recent annual earnings:
Mar 01, 2022Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Nov 04, 2016Analyst ratings
Recent major analysts updates
15 Feb '23 HC Wainwright & Co.
Neutral11 Jan '23 Jefferies
Hold11 Jan '23 Guggenheim
Neutral11 Jan '23 Cowen & Co.
Market Perform10 Jan '23 HC Wainwright & Co.
Neutral09 Jan '23 Wedbush
Neutral13 Oct '22 HC Wainwright & Co.
Buy12 Oct '22 Baird
Outperform08 Sept '22 Guggenheim
Buy16 Aug '22 Wedbush
OutperformScreeners with ALBO included
No data
Market Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
Albireo Pharma doesn't have historical dividend data
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
Similar stocks
FAQ
- What is the primary business of Albireo Pharma?
- What is the ticker symbol for Albireo Pharma?
- Does Albireo Pharma pay dividends?
- What sector is Albireo Pharma in?
- What industry is Albireo Pharma in?
- What country is Albireo Pharma based in?
- When did Albireo Pharma go public?
- Is Albireo Pharma in the S&P 500?
- Is Albireo Pharma in the NASDAQ 100?
- Is Albireo Pharma in the Dow Jones?
- When was Albireo Pharma's last earnings report?
- When does Albireo Pharma report earnings?
- Should I buy Albireo Pharma stock now?
What is the primary business of Albireo Pharma?
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases. The company has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts. As of March 1, 2023, Albireo Pharma, Inc. operates as a subsidiary of Ipsen Biopharmaceuticals, Inc..
What is the ticker symbol for Albireo Pharma?
The ticker symbol for Albireo Pharma is NASDAQ:ALBO
Does Albireo Pharma pay dividends?
No, Albireo Pharma does not pay dividends
What sector is Albireo Pharma in?
Albireo Pharma is in the Healthcare sector
What industry is Albireo Pharma in?
Albireo Pharma is in the Biotechnology industry
What country is Albireo Pharma based in?
Albireo Pharma is headquartered in United States
When did Albireo Pharma go public?
Albireo Pharma's initial public offering (IPO) was on 11 May 2007
Is Albireo Pharma in the S&P 500?
No, Albireo Pharma is not included in the S&P 500 index
Is Albireo Pharma in the NASDAQ 100?
No, Albireo Pharma is not included in the NASDAQ 100 index
Is Albireo Pharma in the Dow Jones?
No, Albireo Pharma is not included in the Dow Jones index
When was Albireo Pharma's last earnings report?
Albireo Pharma's most recent earnings report was on 16 May 2023
When does Albireo Pharma report earnings?
The date for Albireo Pharma's next earnings report has not been announced yet
Should I buy Albireo Pharma stock now?
As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions